Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.21.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2020
Dec. 31, 2019
Current Assets    
Cash and cash equivalents $ 10,931,890 $ 9,039,887
Short-term investments 100,842,438 5,713,922
Accounts receivable 177,239 34,986
Prepaid expenses and other current assets 1,842,620 420,328
Total Current Assets 113,794,187 15,209,123
Property and Equipment, net 676,262 559,410
Other Assets    
In-process R&D 5,866,000 5,866,000
Goodwill 1,452,338 1,452,338
Operating lease right-of-use asset 2,035,882 2,287,500
Finance lease right-of-use asset 247,194 187,573
Deposits 122,779 394,637
Total Other Assets 9,724,193 10,188,048
Total Assets 124,194,642 25,956,581
Current Liabilities    
Accounts payable 1,051,764 1,503,342
Deferred revenue, current portion 603,717 3,410,319
Contingent consideration, current portion   1,124,970
Contingent consideration, related party - current portion   454,364
Operating lease liability, current portion 278,753 216,832
Finance lease liability, current portion 108,127 49,104
Accrued expenses and other liabilities 1,614,534 1,676,467
Total Current Liabilities 3,656,895 8,435,398
Long Term Liabilities    
Other long-term liabilities 36,243  
Derivative warrant liability 33,779  
Deferred tax liability 361,911 361,911
Deferred revenue, net of current portion 237,500 200,000
Operating lease liability, net of current portion 1,301,636 1,519,574
Financing lease liability, net of current portion 160,240 142,667
Contingent consideration, net of current portion 2,250,844 1,653,197
Contingent consideration, related party - net of current portion 661,671 485,984
Total Liabilities 8,700,719 12,798,731
Commitments and Contingencies (Note 9 and 13)
Stockholders' Equity    
Common stock, $.0002 par value; 250,000,000 and 100,000,000 shares authorized, 22,592,500 and 4,826,565 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively 4,519 965
Additional paid-in capital 247,048,349 118,179,635
Accumulated deficit (130,647,485) (104,597,748)
Accumulated other comprehensive loss (166,056) (11,250)
Total Stockholders' Equity - Heat Biologics, Inc. 116,239,327 13,571,602
Non-Controlling Interest (745,404) (413,752)
Total Stockholders' Equity 115,493,923 13,157,850
Total Liabilities and Stockholders' Equity $ 124,194,642 $ 25,956,581